Hoffmann-la Roche Inc.

Roche Palo Alto LLC

F. Hoffmann-la Roche Ag

Andreas Kuglstatter

Thomas Johannes Woltering

Jens-Uwe Peters

Wolfgang Haap

Wolfgang Guba

Ulrike Obst Sander

Mark Rogers-Evans

Bjoern Bartels

Cosimo Dolente

Christian Schnider

Roger Wermuth

Matthew C Lucas

Johannes Cornelius Hermann

Jutta Wanner

Francisco Xavier Talamas

Sharada Shenvi Labadie

Shaoqing Chen

Clara Jeou Jen Lin

Nidhi Arora

Amy Geraldine Moore

Yansheng Zhai

Eva Papp

Walter Vifian

Fernando Padilla

Xiaohu Zhang

Philipp Cueni

The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.

Pyridyl-triazabicycles

The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.

Compounds of the formula I or II: wherein X, m, Ar, Rand Rare as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.

Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators

The present invention provides a compound of formula I' having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease. 

5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines

The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.

BACE1 inhibitors

The present invention relates to the use of novel compounds of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Imidazopyridazine compounds

Growing community of inventors

Loerrach, Germany

Andreas Kuglstatter